| Market Capitalization (Millions $) |
1,882 |
| Shares
Outstanding (Millions) |
116 |
| Employees |
1,605 |
| Revenues (TTM) (Millions $) |
699 |
| Net Income (TTM) (Millions $) |
-149 |
| Cash Flow (TTM) (Millions $) |
-55 |
| Capital Exp. (TTM) (Millions $) |
23 |
Business Description
Novocure Limited is a medical technology company that develops and commercializes innovative cancer treatments based on the combination of electric fields and chemotherapy to disrupt cancer cell division. The company was founded in 2000, and its headquarters are located in Jersey, United Kingdom. It operates with a team of over 1000 employees worldwide, including the United States, Switzerland, Japan, Israel, and Germany, among other countries.
Novocure aims to improve the lives of cancer patients by providing innovative, non-invasive cancer therapies that improve survival rates while maintaining the patient's quality of life. Its primary product, the Optune system, is an FDA-approved device that delivers Tumor Treating Fields (TTFields) to cancer cells, interrupting their division without the toxic side effects of chemotherapy. TTFields use low-intensity electric fields to inhibit cancer cell division, resulting in a slower tumor growth rate and better survival outcomes.
The company's products are used to treat brain tumors, mesothelioma, pancreatic cancer, and non-small cell lung cancer. Novocure has conducted extensive clinical trials on its products, engaging in over 12 clinical trials with a total of over 2000 patients, reporting positive results. The company has also published over 50 peer-reviewed articles showing the efficacy of its Optune system.
Apart from its product pipeline, Novocure has established collaborations with several renowned academic institutions worldwide, including Columbia University, Dartmouth College, and the Mayo Clinic. The company's clinical and R&D teams work closely with these institutions to advance research and clinical studies on cancer treatments.
Novocure Limited aims to become a world leader in cancer care by providing innovative cancer therapies that enhance patient outcomes and reduce treatment-related side effects. The company continues to invest in research & development and clinical studies to further expand the use of Tumor Treating Fields and improve cancer care globally.
Company Address: No. 4 The Forum St. Helier 0
Company Phone Number: 3475 6700 Stock Exchange / Ticker: NASDAQ NVCR
|
108.35 %